Kimberly E. Vanover, Ph.D.

Scientific Advisor & Member, ERG Scientific Liaison Team

  • Over 25 years in the biopharmaceutical industry; has led the discovery and development of small molecule drugs for the treatment of neuropsychiatric and neurodegenerative diseases
  • Works across multiple central nervous system (CNS) therapeutic indications including the areas of schizophrenia, bipolar disorder and other mood disorders, sleep disorders, substance use disorders, and neurodegenerative disorders including Parkinson’s disease and Alzheimer’s disease
  • Has contributed to over a dozen patents and more than 50 peer-reviewed scientific publications and review articles
  • Provides consulting services related to drug development and regulatory strategy through her company, Advan CNS LLC
  • Postdoctoral training at Lederle Laboratories and in the Department of Psychiatry at the University of California, San Diego
  • Received her B.A. in Psychology from the University of Missouri and her Ph.D. in Biopsychology from the University of Chicago